Gender-specific differences in major cardiac events and mortality in lamin A/C mutation carriers

Ingrid A. W. van Rijsingen, Eline A. Nannenberg, Eloisa Arbustini, Perry M. Elliott, Jens Mogensen, Johanna F. Hermans-van Ast, Anneke J. van der Kooi, J. Peter van Tintelen, Maarten P. van den Berg, Maurizia Grasso, Alessandra Serio, Sharon Jenkins, Camilla Rowland, Pascale Richard, Arthur A. M. Wilde, Andreas Perrot, Sabine Pankuweit, Aeilko H. Zwinderman, Philippe Charron, Imke ChristiaansYigal M. Pinto

Research output: Contribution to journalArticleAcademicpeer-review

114 Citations (Scopus)

Abstract

Mutations in the lamin A/C gene (LMNA) cause a variety of clinical phenotypes, including dilated cardiomyopathy. LMNA is one of the most prevalent mutated genes in dilated cardiomyopathy, and is associated with a high risk of arrhythmias, sudden cardiac death, and heart failure. There are few data on the impact of age and gender on cardiac disease penetrance and mortality. In a multicentre cohort of 269 LMNA mutation carriers, we evaluated gender-specific penetrance of cardiac involvement and major cardiac events. All-cause mortality of mutation carriers [standardized mortality ratio (SMR)] was determined. Cardiac disease penetrance was age dependent and almost complete at the age of 70 years. The presence of an LVEF ≤45% was significantly higher in men (P < 0.001). However, there was no difference between genders in the prevalence of atrioventricular block, atrial tachyarrhythmias, and non-sustained ventricular tachycardia. Malignant ventricular arrhythmias (26% vs. 8%) and end-stage heart failure (28% vs. 14%) were more common in men than in women (P < 0.001 and P = 0.006, respectively). All-cause mortality of mutation carriers was significantly increased [SMR 4.0, 95% confidence interval (CI) 2.8-5.2] between the ages of 15 and 75 years. Mortality in men was higher than in women (hazard ratio 2.2, 95% CI 1.2-4.3). This large cohort of LMNA mutation carriers demonstrates a high cardiac disease penetrance and a high mortality in mutation carriers. Male mutation carriers have a worse prognosis due to a higher prevalence of malignant ventricular arrhythmias and end-stage heart failure
Original languageEnglish
Pages (from-to)376-384
JournalEuropean journal of heart failure
Volume15
Issue number4
DOIs
Publication statusPublished - 2013

Cite this